Get the Stockscreener App
318.89
0.26%
-0.83
After Hours:
318.89
Penumbra Inc stock is traded at $318.89, with a volume of 228.14K.
It is down -0.26% in the last 24 hours and down -1.69% over the past month.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
See More
Previous Close:
$319.72
Open:
$319.28
24h Volume:
228.14K
Relative Volume:
0.65
Market Cap:
$12.56B
Revenue:
$1.45B
Net Income/Loss:
$171.05M
P/E Ratio:
73.38
EPS:
4.3459
Net Cash Flow:
$212.73M
1W Performance:
+0.41%
1M Performance:
-1.69%
6M Performance:
-5.17%
1Y Performance:
+27.97%
1-Day Range:
$318.17
$319.61
1-Week Range:
$316.77
$320.27
52-Week Range:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
318.89 | 12.56B | 1.45B | 171.05M | 212.73M | 4.3459 |
ABT
Abbott Laboratories
|
101.29 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.64 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.36 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.92 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.29 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-25 | Initiated | Wells Fargo | Underweight |
| Oct-08-25 | Upgrade | Needham | Hold → Buy |
| Sep-02-25 | Initiated | Evercore ISI | Outperform |
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
The Technical Signals Behind (PEN) That Institutions Follow - Stock Traders Daily
Anaconda Biomed raises $56m for catheter portfolio’s advance - Yahoo Finance
Penumbra stock reports 14.9 percent revenue growth - AD HOC NEWS
Penumbra, Inc. (PEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
ETFs Investing in Penumbra, Inc. Stocks - TradingView
Penumbra, Inc. (PEN) Stock Analysis: Evaluating A 13.93% Upside Potential - DirectorsTalk Interviews
Penumbra Inc. stock trades near 317 dollars as investors weigh growth and valuation - AD HOC NEWS
Penumbra Inc. stock holds near 315 dollars as growth expectations stay high - AD HOC NEWS
Penumbra Stock Price Forecast. Should You Buy PEN? - StockInvest.us
Reasons to Retain Penumbra Stock in Your Portfolio for Now - Eastern Progress
Mechanical Clot Engagement Option for CAVT Thrombectomy Now Available - dicardiology.com
Penumbra Inc. (PEN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Penumbra, Inc. (PEN) Stock Analysis: Navigating Growth With A 13.88% Potential Upside - DirectorsTalk Interviews
Penumbra, Inc. (PEN): Growth Potential Amidst Analyst Consensus And Market Dynamics - DirectorsTalk Interviews
Price to earnings forward of Penumbra, Inc. – NYSE:PEN - TradingView
Discipline and Rules-Based Execution in PEN Response - Stock Traders Daily
BSP:P2NB34 Enterprise Value: R$-100 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 Shareholder Yield %: 0.05% | Fairly Valued - GuruFocus
BSP:P2NB34 Revenue: R$7,963 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 GF Value: R$57.41 | Fairly Valued - GuruFocus
BSP:P2NB34 ROCE %: 10.74% | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Loans Receivable : R$0 Mil (As of Jun. 2026) - GuruFocus
Penumbra Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
BSP:P2NB34 3-Year EPS without NRI Growth Rate: 188.40% — 5 - GuruFocus
Penumbra (BSP:P2NB34) Land And Improvements : R$0 Mil (As of Jun. 2026) - GuruFocus
Q3 2025 Penumbra Inc Earnings Call Transcript - GuruFocus
BSP:P2NB34 Other Current Assets: R$268 Mil | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Total Long-Term Assets : R$3,231 Mil (As of Jun. 2026) - GuruFocus
BSP:P2NB34 Net Income: R$853 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 FCF Yield %: 1.79 — 2457% Above Median - GuruFocus
BSP:P2NB34 Market Cap: R$2,172 Mil | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) 12-1 Month Momentum % : N/A% (As of Sep. 05, 2026) - GuruFocus
BSP:P2NB34 3-Year RORE %: 46.88 | Fairly Valued - GuruFocus
BSP:P2NB34 PE Ratio (TTM): 2.55 — 99% Below Median - GuruFocus
Penumbra (BSP:P2NB34) 3-1 Month Momentum % : N/A% (As of Sep. 04, 2026) - GuruFocus
BSP:P2NB34 Net-Net Working Capital: R$75.32 | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Other Income (Minority Interest) : R$0 Mil (TTM As of Jun. 2026) - GuruFocus
Penumbra (BSP:P2NB34) Repurchase of Stock : R$0 Mil (TTM As of Jun. 2026) - GuruFocus
BSP:P2NB34 Forward PE Ratio: 1.72 | Fairly Valued - GuruFocus
Penumbra Inc Stock Operating Data - GuruFocus
BSP:P2NB34 Pre-Tax Income: R$1,082 Mil | Fairly Valued - GuruFocus
Penumbra, Inc. (PEN) Stock Analysis: Unraveling The 12.48% Potential Upside - DirectorsTalk Interviews
Penumbra Inc. (PEN) Peer Comparison – Compare with Others - Value Research
Penumbra Inc. (PEN) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Penumbra Inc. (PEN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Incuvate Files Patent Infringement Lawsuit Against Penumbra - The Manila Times
Penumbra, Inc. (PEN) Stock Analysis: Exploring Growth Potential And Market Position - DirectorsTalk Interviews
Penumbra (PEN) Financial Update: EPS Does Not Reach the Reported Estimate at the Close; Investor Response: Shares Finish 0.43% DownAnnual Report - careplusvn.com
Trillium Asset Management LLC Acquires New Stake in Penumbra, Inc. $PEN - MarketBeat
BlackRock Inc. Invests $1.36 Billion in Penumbra, Inc. $PEN - MarketBeat
Incuvate Says Penumbra Infringed Blood Clot Detection System (1) - Bloomberg Law News
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):